Genmab A/S : Investor Presentation - August 2020

Innovating

Antibodies,

Improving Lives

Investor Presentation August 2020

Forward Looking Statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

2

Our Core Purpose, Strategy & Vision Guide Our Work

Core Purpose

Our Strategy

Vision

To improve the lives of patients	Turn science into medicine	By 2025, our own product has
by creating & developing innovative		transformed cancer treatment and
antibody products	Build a profitable & successful biotech	we have a pipeline of knock-your-
		socks off antibodies

Focus on Core Competence

3

The Genmab Difference

Innovation Powerhouse Transforming Cancer Treatment & Creating Value

Strong pipeline of 1st-in-class /best-in-class products

Proprietary
technologies	Deep insight into
allow us
antibody biology
to build a
& disease targets
world-class
pipeline
	Match in-house
	expertise with
	strategic
	partnerships

4

Track Record & Growth

Over 20 Years

of Achievement

36 Cumulative INDs since 1999

21 Genmab created product candidates in Ongoing Clinical Trials

3 Genmab-created Products Approved

7 Years of Profitability

• Expanding Top Line
  Dual-listed in US & DK with 2019 US IPO

5

Solid Foundation Built

on a Differentiated Pipeline

Potential 1st-in-Class/Best-in-Class

Our Own Clinical Pipeline

•	Tisotumab Vedotin4	•	DuoBody-CD40x4-1BB6
•	Enapotamab Vedotin	•	DuoBody-PD-L1x4-1BB6
•	HexaBody®-DR5/DR5	•	DuoHexaBody®-CD375
•	Epcoritamab (DuoBody®-CD3xCD20)5	•	DuoBody-CD3x5T45

R&D Engine
Technologies & Pre-Clinical
(innovaTV
•	DuoBody technology
206) study
•	HexaBody technology
•	in	®	technology
HexElect
Japanese		®
•	DuoHexaBody technology
population		8

• Rich Pre-Clinical Pipeline incl. HexaBody-CD38

Solid Financial Base

Approved Partnered Products

•DARZALEX® (daratumumab) / DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)1

• Arzerra® (ofatumumab)2

•TEPEZZA® (teprotumumab)3

Programs Built on Genmab's Innovation

Partner-owned Programs in the Clinic

• 11 product candidates in clinical development w/ partners
• Incl. 6 DuoBody products with Janssen, 1 with Novo Nordisk
• Ofatumumab7 (RMS)

6

1In dev. by Janssen; 2with Novartis; 3In dev. by Horizon; 450:50 w/ Seattle Genetics; 550:50 w/ AbbVie; 650:50 w/ BioNTech, GEN1046 & GEN1042 respectively; 7In dev. by Novartis . 8Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

DARZALEX® (daratumumab) & DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj): Redefining Treatment of Multiple Myeloma

First-in-class CD38 antibody in development to treat cancer

Collaboration with Janssen: Genmab entitled to tiered royalty of 12-20% of net sales

Approved in certain territories for various multiple myeloma (MM) indications1

DARZALEX FASPRO first and only SC CD38 mAb approved in U.S. for treatment of MM

$	2019 WW net sales by J&J: $2,998M
	7
	See local country prescribing information for approved indications

DARZALEX Approvals: US and EU

On Track for Approval Across All Lines of MM Treatment

US Approvals

							US Submissions:
November	November	June 2017,	May 2018,			September 2019,	May 2020,
	June 2019,
2015,	2016, RRMM	RRMM	FLMM NTE	February 2019,	FLMM TE	DARZALEX FASPRO	• RRMM (D-Kd) Feb. 2020
(CASTOR;	FLMM NTE	(COLUMBA;
Monotherapy	(EQUULEUS),	(ALCYONE),	Split dosing	(CASSIOPEIA),
POLLUX),
(MAIA), D-Rd	PLEIADES)
(SIRIUS)	D-Vd,D-Rd	D-Pd	D-VMP		D-VTd

Subcutaneous

EU Approvals

						EU Submissions:
April 2016,	February 2017,	June 2018, FLMM	December	November	January 2020,	June 2020,
Monotherapy	RRMM (CASTOR;	NTE (ALCYONE),	2018,	2019, FLMM	FLMM TE	Subcutaneous
(SIRIUS)	POLLUX), D-Vd,	D-VMP	Split dosing	NTE (MAIA),	(CASSIOPEIA),	(COLUMBA;
	D-Rd		D-Rd	D-VTd
				PLEIADES)

8

Daratumumab

Proving to be the Critical Driver Across Different Combinations & Treatment Lines

sCR Odds Ratio1 or CR+2

MRD-neg rate

PFS risk reduction

	Frontline			Relapsed/Refractory
Transplant Eligible	Transplant Ineligible
Ph 3	Ph 2	Ph 3	Ph 3		Ph 3	Ph 3
CASSIOPEIA1,3	GRIFFIN1,4	ALCYONE2,4	MAIA2,4		POLLUX2,4	CASTOR2,4
(D-VTd vs. VTd)	(D-VRd vs VRd)	(D-VMP vs. VMP)	(D-Rd vs. Rd)		(D-Rd vs. Rd)	(D-Vd vs Vd)
1.60	1.57	~2x	~2x		>2x	3x

1.5x

2.5x

4x

>3x

~5x

>7x

53%	NA	58%	44%	56%	69%
(HR, 0.47)		(HR, 0.42)	(HR, 0.56)	(HR, 0.44)	(HR, 0.31)

Ongoing Phase 3: CEPHEUS (D-VRd, NDMM NTE), PERSEUS (D-VRd, NDMM TE)

3Data as per ASCO 2019; 4Data as per ASH 2019	9

Improved Survival for Patients with Multiple Myeloma

Overall Survival Analysis from ALCYONE Trial

Kaplan-Meier estimates of overall survival in intention-to-treat population. Mateos, MV et al, 'Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly	10
diagnosed multiple myeloma (ALCYONE): a randomized, open-label, phase 3 trial,' The Lancet, published online December 9, 2019

Ofatumumab (OMB 157)

Potential in Relapsing Multiple Sclerosis

Human CD20 Antibody - well validated target

Positive data Phase 3 (ASCLEPIOS I&II) relapsing multiple sclerosis (RMS)

Primary and key secondary endpoints met

ASCLEPIOS I&II: SubQ dosing, 20mg monthly after initial dosing on weeks 0, 1 and 2

Developed by Novartis: Regulatory submissions made in

US & EU

$	Genmab 10% royalty payment of net sales

Second Genmab-created product with blockbuster potential

11

Tisotumab Vedotin

Genmab's Most Advanced Asset with Potential in Solid Tumors

Fully human antibody-drug conjugate (ADC) targeting Tissue

Factor (TF) in development to treat solid tumors

License and collaboration agreement with Seattle

Genetics 50:50

Very favorable topline results, Phase 2 recurrent or metastatic cervical cancer

Ongoing trials in cervical, ovarian cancer, other solid tumors

Expanding development, additional studies planned

12

Tisotumab Vedotin in Cervical Cancer

Designed to Address a High Unmet Medical Need

Recurrent or metastatic cervical cancer	Encouraging Antitumor Activity Observed*

			N=55
• Poor prognosis advanced / recurrent cervical		IRC-Assessed	INV-Assessed
cancer	ORR confirmed + unconfirmed (95% CI), %	35 (22-49)	31 (19-45)
• RR standard therapies generally <15%	ORR confirmed (95% CI), %	22 (12-35)	24 (13-37)
• Median OS 6-8 months
• Data ORR & survival after progression on 1L	CR, n (%)	1 (2)	0
bevacizumab + doublet chemotherapy are limited	PR, n (%)	11 (20)	13 (24)
	SD, n (%)	19 (35	21 (38)
Conclusions*	PD, n (%)	17 (31)	17 (31)
(previously treated recurrent or metastatic cervical cancer)	Not evaluable, n (%)	5 (9)	4 (7)
• Manageable AEs + encouraging antitumor activity	DCR confirmed (95% CI), %	56 (42-70)	62 (48-75)
• ORR 35% (confirmed + unconfirmed, IRC)	Median DOR (range), months	6.0 (+1.0 -9.7)	4.2 (+1.0 -9.7)
• Confirmed ORR 22%	Median PFS (95% CI, months	4.1 (1.7-6.7)	4.2 (2.1-5.3)
• Median DOR 6.0 months	6-month PFS rate (95% CI), %	40 (24-55)	29 (17-43)
• 6-month PFS of 40%
*Data from innovaTV 201 study, Hong DS, et al. Tisotumab Vedotin in Cervical Cancer, SGO March 16-19, 2019		13

Enapotamab Vedotin

Potential in Solid Tumors

Fully human ADC, targets tumor-associated AXL

AXL over-expressed on many resistant tumors

Ph 1/2 study ongoing solid tumors

Expansion cohorts recruiting

ADC technology license from Seattle Genetics

Fully owned by Genmab

14

Epcoritamab (DuoBody-CD3xCD20)

Potential for Improved Efficacy & Safety in B Cell Malignancies

Potential best-in-class therapeutic

T cell-mediated killing of CD20-expressing cells

SubQ Ph 1/2 trial in B cell malignancies ongoing

50:50 co-development Genmab and AbbVie

15

Epcoritamab: Dose Escalation Data Presented at EHA25 Virtual Congress 2020*

Anti-tumor activity

• 86% ORR in FL ≥ 0.76mg
• 60% ORR, incl. 3 pts who failed prior CAR-T treatment, in DLBCL/HGBCL ≥12 mg
• Emerging prelim. data highly encouraging with substantial single-agent efficacy
• Induces rapid and deep responses in heavily pretreated pts with B-NHL across different subtypes

Safety

• No DLTs observed; MTD has not been reached
• No treatment-related deaths
• No discontinuation due to AEs unrelated to disease progression
• No Grade ≥ 3 CRS events observed

T cell	Target
	B cell
	CD3
	CD20

Cytotoxic

activity

Dose-escalation data with subcutaneous epcoritamab indicate potential for best-in-class therapy

*Dose escaltion data presented on EHA25 Virtual Congress 2020 poster, Data cut-off dates: safety, April 24 2020; efficacy, May 14 2020	16

DuoHexaBody-CD37 (GEN3009)

Building Our Pipeline: First DuoHexaBody in the Clinic

Combination of DuoBody & HexaBody platforms

Novel target for hematologic malignancies

Unique mechanism-of-action

Dose escalation ongoing

50:50 co-development Genmab and AbbVie

17

DuoBody-CD3x5T4 (GEN1044)

Latest in the Clinic

Based on proprietary DuoBody technology

CD3 bispecific, T cell mediated cytotoxicity of 5T4+ tumor cells

5T4 expressed on multiple solid tumors limited expression in healthy tissue

Potent anti-tumor activity in diversity pre-clinical models

50:50 co-development Genmab and AbbVie

18

DuoBody-PD-L1x4-1BB (GEN1046)

Bispecific Next Generation Checkpoint Immunotherapy

Bispecific antibody targeting PD-L1 & 4-1BB (CD137)

Potential as differentiated Genmab PD-L1 product

Combining checkpoint blockade with

T cell stimulation

Ph 1/2 study ongoing in solid tumors

50:50 co-development Genmab and BioNTech

19

DuoBody-CD40x4-1BB (GEN1042)

Bispecific Agonistic Antibody

Bispecific antibody targeting CD40 & 4-1BB (CD137)

Conditionally activates T cells and APC in presence of CD40-expressing cells

Phase 1/2 study ongoing in solid tumors

50:50 co-development Genmab and BioNTech

See local country prescribing information for approved indications	20

HexaBody-DR5/DR5 (GEN1029)

First HexaBody in Clinical Development

Targets 2 distinct DR5 epitopes

HexaBody platform - DR5 clustering & DR5 agonist activity

First 100% Genmab-owned HexaBody product in clinic

Phase 1/2 study ongoing in multiple solid tumors

21

2020 Guidance*: Recurring Revenue R&D Investments

Income	DKKM	~USDM**
Statement
Revenue	9,100	- 9,700	1,400	- 1,492
Operating Expenses	(3,850)	- (3,950)	(592)	- (608)
Operating Income	5,200	- 5,800	800 - 892

Growth and Focused

Key Observations

Summary P&L

• DARZALEX royalties of ~DKK 4.1bn to ~DKK 4.5bn to drive recurring revenue growth
• Nearly 90% of USD 750M upfront from AbbVie collab. recognized immediately
• Growth in operating expenses driven by expanding and accelerating our clinical pipeline

DARZALEX Sales of USD 3.9bn - USD 4.2bn

• Significant opportunity for growth in 1L MM market
• SubQ DARZALEX approvals in H1 in U.S. & EU
• Market share gain in the U.S. and RoW driven by uptake in all lines of treatment
• 7 approved indications in U.S., late stage to 1L MM
• Growth expected to normalize in H2 2020

22

* 2020 Guidance does not take into account potential impact of COVID-19. **2020 Guidance - August 12, 2020 / USD 1.00 = DKK 6.50.

Key 2020 Priorities

Building a Strong Differentiated Product Pipeline

Priority	✓	Targeted Milestones
Genmab proprietary*		» Tisotumab vedotin1 - Phase 2 innovaTV 204 safety & efficacy analysis in recurrent/metastatic
products		cervical cancer and engage U.S. FDA for BLA submission subject to trial results
		» Tisotumab vedotin - data on other solid tumor types
		» Enapotamab vedotin - data to support late stage development
	✓ » Epcoritamab (DuoBody-CD3xCD20)2 Phase 1/2 - decision on recommended Phase 2 dose &
		initiate expansion cohorts
		» HexaBody-DR5/DR5 Phase 1/2 - advance dose escalation
	✓ » DuoBody-PD-L1x4-1BB3 Phase 1/2 - initiate expansion cohorts
		» DuoBody-PD-L1x4-1BB initial data in H2 2020
		» File INDs and/or CTAs for 2 new products
Daratumumab4	✓ » U.S. FDA and EMA decision on Phase 3 COLUMBA multiple myeloma SubQ submission
		» sBLA and MAA Submission Phase 3 ANDROMEDA amyloidosis
		» sBLA and MAA submission Phase 3 APOLLO multiple myeloma
Ofatumumab5		» U.S. FDA decision on regulatory dossier submission in multiple sclerosis
Teprotumumab6	✓	» U.S. FDA decision on Phase 3 OPTIC active thyroid eye disease submission

*Certain product candidates in development with partners, as noted.	23
1. 50:50 dev. w/ Seattle Genetics; 2. 50:50 dev w/ AbbVie; 3. 50:50 dev. w/ BioNTech; 4. In dev. by Janssen; 5. In dev. by Novartis; 6. In dev. by Horizon Therapeutics

Delivering on Genmab's Promise:

Innovating Antibodies, Improving Lives

Developing new capabilities to bring own product to market

Pipeline of 1st-in-class /best-in- class therapies advancing through clinic

World-class team with track record of success

Creating

Substantial

Value

Unique R&D engine &	Significant earnings potential
from marketed products
strategic alliances

24

Innovating Antibodies, Improving Lives

Appendix

A Leading International Biotech With Large Free Float

	Approx.	Approx. Warrants
ADSs, Nasdaq	Market Cap
outstanding:
Global Select	DKK 146bn
USA	USD ~23bn	~1.2M (~2%)

Ordinary	Shares	Shares	Diluted shares:
shares Nasdaq	world-wide incl:	outstanding:	~66M
Copenhagen, DK	USA, UK, DK, NL	~65M

As of August 4, 2020	26

Genmab & AbbVie: Collaboration Overview

1. broad, long-term oncology collaboration with Genmab and AbbVie working together to jointly make all strategy, clinical development and commercialization decisions

*Source: Company information and filings.

50/50 partnership across three clinical next- generation bispecific antibody product candidates (epcoritamab, DuoHexaBody-CD37,DuoBody-CD3x5T4)

Genmab to book epcoritamab sales in the U.S. and Japan; AbbVie to commercialize epcoritamab RoW - Genmab to receive tiered royalties on RoW net sales

Worldwide co-commercialization and profit split of all other programs

Discovery Research Collaboration

Fourth* largest oncology partnership with total
potential value ~USD 3.9bn (up-front cash +
milestone payments) to Genmab	27

Advancing Pipeline: Delivering on Our Promise & Creating Value

Accelerating Development of Potential "Next Winners"

Delivering on Genmab's Promise to Patients

DuoBody-CD3xCD20 (epcoritamab)

• Potential best-in-class:SubQ administration
• Pre-clinical /preliminary clinical data shows encouraging safety & efficacy
• Expeditious and comprehensive clinical development plan
• RP2D decision & expansion cohorts initiation
• 50:50 AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

• Potential first-in-class:Next generation IO

• Unmet medical need

• FiH clinical study: escalation phase is ongoing

• 50:50 BioNTech

Delivering on Genmab's

Promise for Patients

Track Record of Success

28

Advancing Pipeline: Delivering on Our Promise & Creating Value

Delivering on Genmab's Promise to Patients

Bolstering early stage portfolio

•DuoBody-CD40x4-1BB1;DuoHexaBody-CD372;DuoBody-CD3x5T42;HexaBody-CD383

Adding new technologies

Data sciences

Expanding early stage discovery programs

Enhancing clinical development capabilities

Track Record of Success

29

1GEN1042, 50:50 w/ BioNTech; 250:50 w/ AbbVie; 3Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement w/ Janssen Biotech, Inc

Genmab's Commitment to Society

Building a Socially Responsible & Sustainable Company

Anchored in our Core Purpose		CSR Committee comprised		Focus on four main areas
	of representatives from
& Vision
variety of functions, chaired by
		CEO
• To improve the lives of	•	Ensures that Genmab carries	•	Employee well-being, including
patients by creating and		out CSR activities effectively		health, safety & development
developing innovative		& communicates clearly and	•	Ethics in relation to pre-clinical
antibody products		openly
		and clinical studies
• By 2025 our own product has	•	Focus on Environment,
•	Environment, including waste
transformed cancer		Society and Governance
		management & recycling
treatment and we have a		reporting
	•	Business ethics & transparency
pipeline of knock-your-socks-

off antibodies

30

Innovation Powerhouse:

Cutting Edge Proprietary Technologies

Technology	Principle	Applications
DuoBody	Bispecific antibodies	Dual targeting

HexaBody	Target-mediated	Enhanced potency
enhanced hexamerization

DuoHexaBody	Bispecific antibodies with target-	Dual targeting +
mediated enhanced
enhanced potency
	hexamerization

HexElect	Two co-dependent antibodies	Dual targeting +
with target-mediated enhanced
enhanced potency & selectivity
	hexamerization

31

Innovative Clinical and Pre-Clinical Pipeline

Genmab's Proprietary1 Products

Product

Target

Developed By Disease Indications

Most Advanced Development Phase

Pre-Clinical

1

1/2

2

3

Approved

Tisotumab vedotin	TF	50:50 Genmab
		/ Seattle
		Genetics

Enapotamab vedotin	AXL	Genmab
Epcoritamab	CD3, CD20	50:50 Genmab
(DuoBody-CD3xCD20)		/ AbbVie
DuoBody-PD-L1x4-1BB	PD-L1,	50:50 Genmab
(GEN1046)	4-1BB	/ BioNTech
HexaBody-DR5/DR5	DR5	Genmab
(GEN1029)
DuoBody-CD40x4-1BB	CD40,	50:50 Genmab
(GEN1042)	4-1BB	/ BioNTech
DuoHexaBody-CD37	CD37	50:50 Genmab
(GEN3009)		/ AbbVie
DuoBody-CD3x5T4	CD3, 5T4	50:50 Genmab
(GEN1044)		/ AbbVie
IND/CTAs in 2020		Genmab
HexaBody-CD38 (GEN3014)2

Cervical cancer

Ovarian cancer

Solid tumors

Solid tumors

Hematological malignancies

Solid tumors

Solid tumors

Solid tumors

Hematologic malignancies

Solid tumors

32

1Certain product candidates in development with partners, as noted. 2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc

Products Created by Genmab*

Including Proposed Label Expansions for Marketed Products

Product

Target

Developed By

Disease Indications

Most Advanced Development Phase

DARZALEX	CD38 Janssen (Tiered
(daratumumab) &	royalties to Genmab
DARZALEX	on net global sales)
FASPRO
(daratumumab and
hyaluronidase-fihj)
Daratumumab

Arzerra	CD20 Novartis (Royalties
(ofatumumab)		to Genmab on net
		global sales)
TEPEZZA		Horizon
(teprotumumab-trbw)		Therapeutics (under
	IGF-1R	sublicense from
	Roche, royalties to

Genmab on net global sales)

Pre-Clinical	1	1/2	2	3	Approved
Multiple myeloma1
AL Amyloidosis
Non-MM blood cancers

Chronic lymphocytic leukemia1,2

Thyroid eye disease1

*Out-licensed products marketed by partner 1See local country prescribing information for precise indications, 2Not in active development

Partner-owned Products Incorporating Genmab's Innovation*

Product	Target	Developed By	Disease Indications	Most Advanced Development Phase
				Pre-Clinical	1	1/2	2	3	Approved

Ofatumumab	CD20	Novartis
(OMB157)
Camidanlumab tesirine
(ADCT-301)	CD25	ADC Therapeutics
Mim8	FIX(a), FX	Novo Nordisk
Amivantamab	EGFR, cMet	Janssen
(JNJ-61186372)
JNJ-63709178	CD123, CD3	Janssen
Teclistamab	BCMA, CD3	Janssen
(JNJ-64007957)
Talquetamab	GPRC5D, CD3	Janssen
(JNJ-64407564)
JNJ-67571244	CD33, CD3	Janssen
JNJ-63898081	PSMA, CD3	Janssen
HuMax-IL8	IL8	BMS
Lu AF82422	alpha-Synuclein	Lundbeck
~20 active pre-clinical
programs

*Out-licensed Products under development by a third-party incorporating Genmab technology and innovation

Relapsing MS
Relapsed /Refractory Hodgkin
Lymphoma
Solid tumors
Healthy volunteers & hemophilia A
Non-small-cell lung cancer (NSCLC)
Acute Myeloid Leukemia (AML)
Relapsed or refractory MM
Relapsed or refractory MM
Relapsed or refractory AML or MDS
Solid tumors
Advanced cancers
Parkinson's disease
Partnered & proprietary programs:
HuMab, DuoBody, DuoHexaBody	34
and HexaBody

Solid Foundation Built on a Differentiated Pipeline

Tisotumab Vedotin Clinical Program

innovaTV 204

Recurrent or metastatic

cervical cancer

• Potentially registrational 102 pts
• Single arm, monotherapy
• 1° endpoint: confirmed ORR
• 2° endpoints: duration of response, PFS, OS

innovaTV 205

Recurrent or metastatic

cervical cancer

• In combo or mono

w/ bevacizumab, pembrolizumab, or carboplatin or weekly monotherapy recurrent or stage IVB cervical cancer

• Up to 170 pts
• 1° endpoint: ORR
• 2° endpoints: Safety, duration of response, time to response,
  PFS, OS

innovaTV 207

Solid tumors

• Basket study
• Up to 250 pts
• Single arm, monotherapy
• 1° endpoint: ORR
• 2° endpoints: Safety, disease control rate, duration of response, time to response,
  PFS, OS

innovaTV 208

Ovarian cancer

• Ovarian cancer, fallopian tube cancer, peritoneal cancer
• Up to 182 pts, incl 12 pt safety run-in
• Monotherapy
• 2 schedules: q3wk & dose dense
• 1° endpoints: Safety & ORR

35

Tisotumab Vedotin

Cervical Cancer Market Size

United States3	Japan6		Europe2
New Diagnoses	Deaths	New Diagnoses	Deaths	New Diagnoses	Deaths
12,578	4,115	9,390	3,654	58,373	24,404

3rd most common gynecologic	2nd most common gynecologic	3rd most common gynecologic
cancer in US4	cancer in Japan6	cancer in Europe2*

In developed countries, incidence rates are low (<7.9 per 100,000 women) compared with developing countries

in sub-Saharan Africa and Central and South America, where incidence is especially high (>30 per 100,000 women)5

*Europe is defined as the 40 countries in the four United Nations-defined areas of Europe and the European Union (EU-27).

References: 1. American Cancer Society 2. .EUCAN (2012) 3. Centers for Disease Control and Prevention. Cervical Cancer Statistics (2017) 4. UpToDate.36 5. Ginsburg O et al. Lancet 2017 6. HPV Information Centre Japan (2017)

HexaBody-CD38 (GEN3014)

Expanding the Potential of CD38 Antibodies

Incorporates	Highly promising	Could potentially	IND/CTA planned
proprietary	data pre-clinical	add to and broaden	in H2 2020
HexaBody	models for MM,	DARZALEX
technology	lymphoma & AML	franchise

37

Covering All Stages of MM and Beyond: Key Ongoing* Industry Sponsored Trials

Disease

High Risk Smoldering MM

Front line MM (transplant & non- transplant)

Relapsed or Refractory MM

ALL

Therapy

Subcutaneous

Monotherapy

Dara + VRd

Dara + VMP (Asia Pacific)

Dara + VRd

Dara + R (maintenance)

Dara + combinations

Dara + I.O. (PD1 & PDL1)

Dara + SoC chemo

Development Phase

Pre-Clinical

1

1/2

2

3

✓AQUILA ✓CENTAURUS

✓CEPHEUS

✓OCTANS

✓PERSEUS

AURIGA

NINLARO® (Ph II), Venclexta® (Ph II), Selinexor (Ph I/II)

Opdivo® (Ph I/II), Tecentriq® (Ph I)

DELPHINUS

V = Velcade® , MP = melphalan-prednisone , T = thalidomide d = dexamethasone, R = Revlilmid®, K = Kyprolis®, Pom = Pomalyst®

• Fully recruited

*Does not include trials that may still be ongoing but have clinical data and/ or	38
are the basis for an existing approval.

Daratumumab Efficacy in Newly Diagnosed Multiple Myeloma

Updated Phase 3 MAIA Trial (D+Rd, NTE): ASH Dec 2019

• Median PFS not reached in D-Rd arm

• MRD-negativity significantly higher with D-Rd vs. Rd (29% vs 9%; P<0.0001)

• No new safety concerns

• Results continue to support use of D-Rd in 1st line treatment of TIE pts with NDMM

39

D = daratumumab; R = lenalidomide; d = dexamethasone; PFS = progression free survival; MRD - minimal residual disease

Ongoing Daratumumab Clinical Trials

Janssen Sponsored Phase 3 & 4

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03768960	4	J&J Private Ltd	Relapsed or Refractory MM	Daratumumab (MMY4008)
NCT02252172	3	Janssen	Untreated MM	Daratumumab + Rd (MAIA)
NCT02195479	3	Janssen	Untreated MM	Daratumumab + VMP (ALCYONE)
NCT02541383	3	Janssen	Untreated MM	Daratumumab + VTd (CASSIOPEIA)
NCT02076009	3	Janssen	Relapsed or Refractory MM	Daratumumab + Rd (POLLUX)
NCT02136134	3	Janssen	Relapsed or Refractory MM	Daratumumab + Vd (CASTOR)
NCT03180736	3	Janssen	Relapsed or Refractory MM	Daratumumab + Pom-d (APOLLO)
NCT03201965	3	Janssen	Amyloidosis	Daratumumab + CyBorD (ANDROMEDA)
NCT03217812	3	Janssen	Untreated MM	Daratumumab + VMP (Asia Pacific) (OCTANS)
NCT03234972	3	Janssen	Relapsed or Refractory MM	Daratumumab + Vd vs Vd (LEPUS)
NCT03277105	3	Janssen	Relapsed or Refractory MM	Daratumumab SubQ vs IV (COLUMBA)
NCT03301220	3	Janssen	Smoldering MM	Daratumumab SC (AQUILA)
NCT03652064	3	Janssen	Untreated MM	Daratumumab + VRd (CEPHEUS)
NCT03710603	3	Janssen/EMN	Untreated MM	Daratumumab + VRd (PERSEUS)
NCT03901963	3	Janssen	Untreated MM / Maintenance	Daratumumab + R (AURIGA)

40

Ongoing Daratumumab Clinical Trials

Janssen Sponsored Phase 1 & 2

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier	Phase	Sponsor	Indication	Therapy
NCT03384654	2	Janssen	Relapsed / Refractory ALL / LL	Dara + Vincristine + Prednisone + Doxorubicin (DELPHINUS)
NCT02951819	2	Janssen	Untreated and Relapsed MM	Daratumumab + CyBorD (LYRA)
NCT02874742	2	Janssen	Untreated MM	Daratumumab + VRd (GRIFFIN)
NCT02316106	2	Janssen	Smoldering MM	Monotherapy (CENTAURUS)
NCT02927925	2	Janssen	NKTCL, Nasal Type	Monotherapy (VOLANS)
NCT03412565	2	Janssen	Newly diag. & relapsed / refractory MM Daratumumab SubQ + Rd, VMP & VRd (PLEIADES)
NCT03871829	2	Janssen	Dara retreatment	Daratumumab SubQ+ Kd vs Kd (LYNX)
NCT03011034	2	Janssen	MDS	Daratumumab (or talacotuzumab) (MDS2002)
NCT01615029	1/2	Janssen	Relapsed and Refractory MM	Daratumumab + Rd (GEN503)
NCT02852837	1	Janssen	Relapsed or Refractory MM	Monotherapy (in China) (MMY1003)
NCT02519452	1	Janssen	Relapsed or Refractory MM	Monotherapy, subcutaneous (PAVO)
NCT02918331	1	Janssen	Untreated MM	Daratumumab + Rd (Japan) (MMY1006)
NCT03242889	1	Janssen	Relapsed or Refractory MM	Daratumumab subq (Japan) (MMY1008)
NCT01998971	1	Janssen	Various MM	Daratumumab + backbone regimens (Vd, VMP, VTd, Pom-d, Kd, KRd)
(EQUULEUS)
NCT04108195	1	Janssen	Multiple Myeloma	Daratumuamb + either talquetamab or teclistamab (MMY1002)
NCT04121260	1	Janssen	Multiple Myeloma	Subcutaneous monotherapy (in China) (MMY1010)

41

Ongoing Daratumumab Clinical Trials

Other Industry Sponsored Trials

Daratumumab Trials Sponsored by Pharma / Biotech

Ct.gov Identifier Phase

NCT03158688 3

NCT01946477 2

NCT02807454 2

NCT03439293 2

NCT03314181 2

NCT02807558 2

NCT02773030 1/2

NCT02343042 1/2

NCT03481556 1/2

NCT01592370 1/2

NCT03837509 1/2

NCT03989414 1/2

NCT02431208 1

NCT03068351 1

NCT04045028 1

NCT04136756 1

Sponsor	Indication	Therapy
Amgen	Relapsed or Refractory MM	Daratumumab + Kd (CANDOR)
Celgene	Relapsed or Refractory MM	Daratumumab + Pom-d
Celgene	Relapsed and Refractory MM	Daratumumab + Imfinzi (FUSION)
Takeda	Relapsed or Refractory MM	Daratumumab + NINLARO (ixazomib) + Dex
AbbVie	Relapsed or Refractory MM	Daratumumab + Venetoclax + Dex (w/ or w/out bortezomib)
Syros Pharma	AML or MDS	Daratumumab + SY-1425
Celgene	Relapsed or Refractory MM	Daratumumab + CC-220 + Dex
Karyopharm	Relapsed or Refractory MM	Daratumumab + Selinexor + Dex (STOMP)
Oncopeptides	Relapsed or Refractory MM	Daratumumab + Melflufen + Dex (ANCHOR)
AB
BMS	Relapsed or Refractory MM	Daratumumab + nivolumab
Incyte	Relapsed or Refractory MM	Daratumumab + INCB001158
Celgene	Various MM	Daratumumab + CC-92480
Roche	Resistant or Refractory MM	Daratumumab + Tecentriq (atezolizumab)
Roche	Resistant or Refractory MM	Daratumumab + RO6870810
Genentech	Relapsed or Refractory MM	Daratumumab + tiragolumab
Nektar Thera.	Salvage for MM	Daratumumab + NKTR-255

42

www.genmab.com